A Phase 2 Study to Determine the Safety and Efficacy of Inhaled Dry Powder Mannitol in Cystic Fibrosis
Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
Cystic fibrosis is the most frequent lethal genetic disease of childhood. Causes disruption
of glandular function of the pancreas, intestine, liver, lungs (causing chronic lung
infection with emphysema), sweat glands and reproductive organs. We know that many CF
patients die of lung failure, brought about in part by repeated lung infections caused by
thick, sticky mucus that cannot be readily cleared from the lung.
Inhaled mannitol is an osmotic agent that has been investigated in a number of small studies
that have examined mucociliary clearance, quality of life and lung function in CF and
bronchiectasis. The promising results of these studies warrant futher investigation. The aim
of this study is to assess the safety and efficacy of inhaled mannitol when administered
twice a day over two weeks in CF.